News
Imfinzi becomes first NHS drug for aggressive lung cancer
AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer.
Oncology
The role of advanced imaging in transforming early detection...
The future of prostate cancer care lies in reimagining how we diagnose and monitor the disease.
Oncology
Sponsored
12 Questions with Rick Coope
Rick Coope is General Manager at Menarini Stemline UK, Ireland, and the Nordics.
Oncology
Doing good in people’s lives: Amy Burroughs discusses CML
Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.
News
J&J claims FDA okay for bladder cancer drug TAR-200
Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
